Jonathan P. Orme

785 total citations
13 papers, 184 citations indexed

About

Jonathan P. Orme is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Jonathan P. Orme has authored 13 papers receiving a total of 184 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 6 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Jonathan P. Orme's work include Lung Cancer Treatments and Mutations (8 papers), Innovative Microfluidic and Catalytic Techniques Innovation (3 papers) and HER2/EGFR in Cancer Research (3 papers). Jonathan P. Orme is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Innovative Microfluidic and Catalytic Techniques Innovation (3 papers) and HER2/EGFR in Cancer Research (3 papers). Jonathan P. Orme collaborates with scholars based in United Kingdom, United States and Germany. Jonathan P. Orme's co-authors include Darren A.E. Cross, Matthew J. Martin, Nicolas Floc’h, Philip C. Mack, Jonathan W. Riess, Mingshan Cheng, Darren McKerrecher, M. Raymond V. Finlay, Maria Emanuela Cuomo and James Keck and has published in prestigious journals such as Cancer Research, Scientific Reports and European Journal of Cancer.

In The Last Decade

Jonathan P. Orme

12 papers receiving 179 citations

Peers

Countries citing papers authored by Jonathan P. Orme

Since Specialization

Citations

This map shows the geographic impact of Jonathan P. Orme's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan P. Orme with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan P. Orme more than expected).

Fields of papers citing papers by Jonathan P. Orme

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan P. Orme. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan P. Orme. The network helps show where Jonathan P. Orme may publish in the future.

Co-authorship network of co-authors of Jonathan P. Orme

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan P. Orme. A scholar is included among the top collaborators of Jonathan P. Orme based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan P. Orme. Jonathan P. Orme is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	CLANet: A comprehensive framework for cross-batch cell line identification using brightfield images 2024 ·Medical Image Analysis ·Lei Tong, Adam Corrigan, (unknown), (unknown), Jonathan P. Orme, Yinhai Wang, Huiyu Zhou	1
2	Vinylpyridine as a Tunable Covalent Warhead Targeting C797 in EGFR 2024 ·ACS Medicinal Chemistry Letters ·Nils Pemberton, (unknown), Argyrides Argyrou, Emma Evertsson, Anders Gunnarsson, Jason G. Kettle, Jonathan P. Orme, Richard A. Ward	0
3	An automated cell line authentication method for AstraZeneca global cell bank using deep neural networks on brightfield images 2022 ·Scientific Reports ·Lei Tong, Adam Corrigan, (unknown), (unknown), Jonathan P. Orme, Yinhai Wang, Huiyu Zhou	3
4	Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I 2020 ·Molecular Cancer Therapeutics ·Nicolas Floc’h, Sangbin Lim, (unknown), Afshan Ahmed, Jonathan P. Orme, Jelena Urosevic, Matthew J. Martin, Darren A.E. Cross, Byoung Chul Cho, Paul D. Smith	38
5	Abstract 4813: Comparative activity profiling of tyrosine kinase inhibitors (TKIs) against exon 20 insertions and the wild-type form of epidermal growth factor receptor (EGFR) 2019 ·Cancer Research ·Richard A. Ward, Ambra Bianco, Nicola Colclough, Darren A.E. Cross, (unknown), M. Raymond V. Finlay, Martina Fitzek, Nicolas Floc’h, Sladjana Gagrica, Beverley Hammond, Matthew J. Martin, Darren McKerrecher, Daniel O’Neill, Jonathan P. Orme, Paul D. Smith, Anna D. Staniszewska, Jelena Urosevic, Nicky Whalley, James Yates	1
6	Abstract 4451: Evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation 2019 ·Cancer Research ·Nicolas Floc’h, M. Raymond V. Finlay, Ambra Bianco, (unknown), Nicola Colclough, Darren A.E. Cross, (unknown), Carine Guérot, David Hargreaves, Matthew J. Martin, Darren McKerrecher, Daniel O’Neill, Jonathan P. Orme, Amar Rahi, Paul Smith, Richard A. Ward	9
7	Abstract 4451: Evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation 2019 ·Nicolas Floc’h, M. Raymond V. Finlay, Ambra Bianco, (unknown), Nicola Colclough, Darren A.E. Cross, (unknown), Carine Guérot, David Hargreaves, Matthew J. Martin, Darren McKerrecher, Daniel O’Neill, Jonathan P. Orme, Amar Rahi, Paul D. Smith, Richard A. Ward	1
8	Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions 2018 ·Molecular Cancer Therapeutics ·Nicolas Floc’h, Matthew J. Martin, Jonathan W. Riess, Jonathan P. Orme, Anna D. Staniszewska, Ludovic Ménard, Maria Emanuela Cuomo, Daniel O’Neill, Richard A. Ward, M. Raymond V. Finlay, Darren McKerrecher, Mingshan Cheng, (unknown), Rebekah A. Burich, James Keck, David R. Gandara, Philip C. Mack, Darren A.E. Cross	85
9	Positioning High-Throughput CETSA in Early Drug Discovery through Screening against B-Raf and PARP1 2018 ·SLAS DISCOVERY ·Joseph Shaw, Ian L. Dale, Paul Hemsley, Lindsey Leach, (unknown), Jonathan P. Orme, (unknown), A.J. Narvaez, Michał Biśta, Daniel Martinez Molina, Michael Dabrowski, Martin J. Main, Davide Gianni	31
10	Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation 2016 ·ACS Medicinal Chemistry Letters ·Edward J. Hennessy, Claudio Chuaqui, Susan Ashton, Nicola Colclough, Darren A.E. Cross, J.E. Debreczeni, Cath Eberlein, Lakshmaiah Gingipalli, Teresa Klinowska, Jonathan P. Orme, Sha Li, Xiaoyun Wu	7
11	Osimertinib (AZD9291), an irreversible 3rd generation TKI, induces tumor growth inhibition in NSCLC pre-clinical models harboring the most prevalent EGFR Ex20Ins (in vitro and in vivo) 2016 ·European Journal of Cancer ·Richard A. Ward, S. Ashton, A R Bianco, Nicola Colclough, Darren A.E. Cross, (unknown), M. Raymond V. Finlay, Nicolas Floc’h, Martina Fitzek, Michel Martin, Ludovic Ménard, Darren McKerrecher, Daniel O’Neill, Jonathan P. Orme, (unknown), Anna D. Staniszewska, James Yates	1
12	Cellular Assay Optimization: Part I: The Use of Large-Scale Transiently Transfected Cryobanks and Introduction of a c-Myc Tag to Design a Standardized ELISA Process 2011 ·SLAS DISCOVERY ·(unknown), David I. Fisher, Karen Roberts, Jonathan P. Orme	4
13	Cellular Assay Optimization: Part II: The Use of a Simple Integrated Robotic Work Cell to Allow the Multiplexed Batching of Cellular Assays 2011 ·SLAS DISCOVERY ·(unknown), Jonathan P. Orme, Karen Roberts	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact